Lipid Nanocarrier-Based Drug Delivery Systems: Therapeutic Advances in the Treatment of Lung Cancer
So-Jung Kim,Nidhi Puranik,Dhananjay Yadav,Jun-O Jin,Peter CW Lee
DOI: https://doi.org/10.2147/IJN.S406415
IF: 7.033
2023-05-18
International Journal of Nanomedicine
Abstract:So-Jung Kim, 1, &ast Nidhi Puranik, 2, &ast Dhananjay Yadav, 3, &ast Jun-O Jin, 1 Peter CW Lee 4 1 Department of Microbiology, University of Ulsan College of Medicine, Seoul, 05505, South Korea; 2 Department of Biochemistry & Genetics, Barkatullah University, Bhopal, Madhya Pradesh, 462026, India; 3 Department of Life Science, Yeungnam University, Gyeongsan, 38541, Korea; 4 Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine, ASAN Medical Center, Seoul, 05505, South Korea &astThese authors contributed equally to this work Correspondence: Peter CW Lee, Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine, ASAN Medical Center, Seoul, 05505, Korea, Email Jun-O Jin, Department of Microbiology, University of Ulsan College of Medicine, Seoul, 05505, Korea, Email Although various treatments are currently being developed, lung cancer still has a very high mortality rate. Moreover, while various strategies for the diagnosis and treatment of lung cancer are being used in clinical settings, in many cases, lung cancer does not respond to treatment and presents reducing survival rates. Cancer nanotechnology, also known as nanotechnology in cancer, is a relatively new topic of study that brings together scientists from a variety of fields, including chemistry, biology, engineering, and medicine. The use of lipid-based nanocarriers to aid drug distribution has already had a significant impact in several scientific fields. Lipid-based nanocarriers have been demonstrated to help stabilize therapeutic compounds, overcome barriers to cellular and tissue absorption, and improve in vivo drug delivery to specific target areas. For this reason, lipid-based nanocarriers are being actively researched and used for lung cancer treatment and vaccine development. This review discusses the improvements in drug delivery achieved with lipid-based nanocarriers, the obstacles that still exist with in vivo applications, and the current clinical and experimental applications of lipid-based nanocarriers in lung cancer treatment and management. Keywords: lung cancer, lipid-based nanocarriers, liposome, drug delivery system Lung cancer (LC) is a global health issue affecting approximately 2.1 million people and causing 1.8 million deaths per year. While LC rates continue to rise worldwide, they are decreasing among men in several Western countries. The morphological, etiological, and molecular aspects of LC have been extensively studied. 1,2 The most common cases of LC are usually of two types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), comprising 85% and 15% of patients, respectively. Histological studies, immunological studies, and molecular analyses are used to make a pathological diagnosis, while the eighth edition of the Tumor, Node, Metastasis (TNM) classification for LC is currently used to stage LC. Awareness of the tumor stage is crucial for diagnosis and treatment. The five-year survival rate is approximately 15–20%. Non-small cell lung cancer has four stages: stage I, which is most common in the lung but does not extend to lymph nodes; stage II, which spreads to lymph nodes close to the lungs; stage three, which spreads further into your lymph nodes and the middle of your chest; and stage four, in which the cancer has spread broadly throughout the body. These rates approach 90% for patients with stage 1A1 NSCLC, but fall to below 10% for those with stage 4. 3 Patients with SCLC have a 30% chance of developing a modest illness and a 10% chance of developing severe disease. Surgery, radiation, systemic therapy (targeted therapies, chemotherapy, and immune checkpoint inhibitors), supportive care, and hospice care are used in the management of patients with LC. Treatment is determined by tumor features, tumor stage, and other patient-related factors. Nevertheless, for many countries, obtaining and reimbursing innovative pharmaceuticals is becoming increasingly difficult. 4 Various attempts have been made to treat LC. 5,6 Among these, targeted therapy has recently attracted some attention. Targeted therapy induces the selective death of cancer cells by detecting specific substances, such as hormone receptors, expressed in these cells. 5 Therefore, in many cases, anticancer drugs are delivered together with a target substance to improve the efficiency of the targeted therapy. Recently, nanocarriers have been actively used to deliver anticancer drugs and their target substances. Various materials have been researched and developed as nanocarriers after considering their biostability. 7,8 Lipid-based nanoparticles are one of th -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology